This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Inorbit Therapeutics Ab. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Innovations in Modulating the Farnesoid X Receptor: Lambertus Benthem
Introduction
Lambertus Benthem is an innovative inventor based in Billdal, Sweden. He has made significant contributions to the field of biotechnology, particularly through his research on farnesoid X receptor (FXR) modulation. His work focuses on developing compounds that offer potential therapeutic benefits in treating various diseases associated with FXR.
Latest Patents
Lambertus Benthem holds a patent titled "Compounds useful in modulating the farnesoid X receptor and methods of making and using the same." This patent presents a range of compounds that serve as FXR modulators, which can be beneficial in addressing conditions such as bile acid-related disorders, metabolic syndrome, type-2 diabetes, and several types of cancers. The patented compounds fall under the category of sulfinic acid compounds and can exist in various forms, including enantiomers, stereoisomers, and pharmaceutically acceptable salts. The patent outlines methods for preparing these compounds and their possible applications in medicine.
Career Highlights
Benthem is currently associated with Inorbit Therapeutics AB, where he continues his research and development endeavors. His dedication to advancing therapeutic solutions for complex diseases showcases his commitment to innovation in the biomedical field. With just one patent under his name, Lambertus shows potential for further contributions to science and medicine.
Collaborations
During his career, Lambertus Benthem has worked alongside notable coworkers, including Rajiv Sharma and Robert Andrew Judkins. These collaborations enhance the innovative environment at Inorbit Therapeutics AB and foster the development of novel solutions in healthcare.
Conclusion
Lambertus Benthem stands out as a promising inventor in the realm of biopharmaceuticals. His patent on FXR-modulating compounds signifies a crucial step forward in treating diverse disorders. As he continues to work collaboratively within the innovative team at Inorbit Therapeutics AB, the potential for further groundbreaking inventions remains high, contributing to the advancement of medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile